No­var­tis bur­nish­es Zol­gens­ma da­ta in presymp­to­matic pa­tients as Roche's Evrys­di con­tin­ues eat­ing away at the SMA pie

With sales slow­ing and Roche’s Evrys­di hot on its tail, No­var­tis’ Zol­gens­ma for spinal mus­cu­lar at­ro­phy is seek­ing to build a sta­ble of da­ta in presymp­to­matic pa­tients to give it a po­ten­tial new edge. On Fri­day, the Swiss bio­phar­ma teased out some of the first such re­sults.

Zol­gens­ma met its pri­ma­ry and sec­ondary end­points in a Phase III study co­hort, No­var­tis said, show­ing that all 14 pa­tients man­aged to sit in­de­pen­dent­ly for 30 sec­onds and were alive with­out breath­ing sup­port at 14 months old. The da­ta come from a group of presymp­to­matic pa­tients with two copies of the SMN2 gene aged six weeks or younger at the time of ad­min­is­tra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER